Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 6, 1999, Pages 589-593

  Villikka, Kirsti ^a   Kivistö, Kari T ^b   Mäenpää, Hanna ^b   Joensuu, Heikki ^b   Neuvonen, Pertti J ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 3A4; DEXAMETHASONE; FLUOXETINE; GABAPENTIN; GLIBENCLAMIDE; LEVOMEPROMAZINE; LOMUSTINE; MELPERONE; OXCARBAZEPINE; OXYBUTYNIN; PHENYTOIN; PROCARBAZINE; RANITIDINE; TEMAZEPAM; VIGABATRIN; VINCRISTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0033398416     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0009-9236(99)90067-x     Document Type: Article

References (20)

1. 1. Jackson DV, Castle MC, Bender RA. Biliary excretion of vincristine. Clin Pharmacol Ther 1978;24:101-7.
2. 2. Zhou XJ, Zou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem Pharmacol 1993;45:853-61.
3. 3. Zhou-Pan XR, Sérée E, Zhou XJ, Placidi M, Maurel P, Barra Y, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53:5121-6.
4. 4. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998;18:1304-7.
5. 5. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update [review]. Clin Pharmacokinet 1996;31:198-214.
6. 6. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (Part II) [review]. Clin Pharmacokinet 1990;18:131-50.
7. 7. Ramirez J, Ogan K, Ratain MJ. Determination of vinca alkaloids in human plasma by liquid chromatography/ atmospheric pressure chemical ionization mass spectrometry. Cancer Chemother Pharmacol 1997;39:286-90.
8. 8. Böhme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995;71:311-2.
9. 9. Fedeli L, Colozza M, Boschetti E, Sabalich I, Aristei C, Guerciolini R, et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 1989;64: 1805-11.
10. 10. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine and phenytoin. Epilepsia 1996;37:253-7.
11. 11. Kivistö KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions [review]. Br J Clin Pharmacol 1995;40:523-30.
12. 12. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993;33:181-6.
13. 13. Rodman JH, Murry DJ, Madden T, Santana VM. Pharmacokinetics of high doses of etoposide and the influence of anticonvulsants in pediatric cancer patients [abstract]. Clin Pharmacol Ther 1992;51:156.
14. 14. Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10:311-5.
15. 15. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy [review]. Mol Carcinog 1995;13:129-34.
16. 16. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-8.
17. 17. Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit 1993;15:39-42.
18. 18. Pichard L, Fahre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992;41:1047-55.
19. 19. McCune J, Hawke R, LeCluyse E, Gillenwater H, Ritchie J, Lindey C. Dexamethasone induction of cytochrome P450 3A4 activity in human hepatocytes and healthy volunteers [abstract]. Clin Pharmacol Ther 1999;65:195.
20. 20. Villikka K, Kivistö KT, Neuvonen PJ. Effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 1998;83:135-8.